Market Overview

Why Metacrine's Stock Is Trading Higher Today


Metacrine (NASDAQ: MTCR) shares are trading higher on Monday after multiple firms initiated coverage on the stock with a bullish rating.

Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases.

Metacrine shares traded up 6.83% to $10.86 on Monday at the time of publication. The stock has a 52-week high of $16.19 and a 52-week low of $9.06.

Latest Ratings for MTCR

Oct 2020Canaccord GenuityInitiates Coverage OnBuy
Oct 2020RBC CapitalInitiates Coverage OnOutperform
Oct 2020JefferiesInitiates Coverage OnBuy

View More Analyst Ratings for MTCR
View the Latest Analyst Ratings


Related Articles (MTCR)

View Comments and Join the Discussion!

Posted-In: why it's movingInitiation Analyst Ratings

Latest Ratings

FBTruist SecuritiesMaintains310.0
GOOGLDeutsche BankMaintains2,250.0
FBWells FargoMaintains330.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at